These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34589394)

  • 1. Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy.
    Li K; You J; Wu Q; Meng W; He Q; Yang B; Zhu C; Cao J
    Acta Pharm Sin B; 2021 Sep; 11(9):2738-2748. PubMed ID: 34589394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.
    Vymětalová L; Kryštof V
    Med Res Rev; 2015 Nov; 35(6):1156-74. PubMed ID: 26114963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
    Goel B; Tripathi N; Bhardwaj N; Jain SK
    Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway.
    Shen S; Dean DC; Yu Z; Duan Z
    Hepatol Res; 2019 Oct; 49(10):1097-1108. PubMed ID: 31009153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.
    Lin ZP; Zhu YL; Ratner ES
    Front Oncol; 2018; 8():303. PubMed ID: 30135856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27.
    García-Gutiérrez L; Bretones G; Molina E; Arechaga I; Symonds C; Acosta JC; Blanco R; Fernández A; Alonso L; Sicinski P; Barbacid M; Santamaría D; León J
    Sci Rep; 2019 Dec; 9(1):18693. PubMed ID: 31822694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.
    Thng DKH; Toh TB; Chow EK
    Trends Pharmacol Sci; 2021 Mar; 42(3):166-182. PubMed ID: 33422376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.
    Mizuarai S; Irie H; Schmatz DM; Kotani H
    Curr Mol Med; 2008 Dec; 8(8):774-83. PubMed ID: 19075675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F.
    Leone G; DeGregori J; Sears R; Jakoi L; Nevins JR
    Nature; 1997 May; 387(6631):422-6. PubMed ID: 9163430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
    Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
    Eguchi T; Itadani H; Shimomura T; Kawanishi N; Hirai H; Kotani H
    Mol Cancer Ther; 2009 Jun; 8(6):1460-72. PubMed ID: 19509251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myc and cell cycle control.
    Bretones G; Delgado MD; León J
    Biochim Biophys Acta; 2015 May; 1849(5):506-16. PubMed ID: 24704206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
    Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
    Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.